Pfizer to close two production facilities in North Carolina
chensong665124
发表于 2023-10-28 09:42:54
3319
0
0
Pfizer will close two production facilities in North Carolina. Pfizer stated in an email statement that the company will close its Kit Creek and Durham clinical manufacturing facilities in North Carolina. The company stated that closing these factories is part of Pfizer's previously announced cost adjustment plan. Pfizer continues to operate its largest factory in North Carolina, including two in Sanford and one in Rocky Mountains.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Stellantis suspends production at two factories in Italy
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Intel CEO suddenly announces retirement, with interim executive chairman and two interim CEOs appointed during the transition period
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy